Reuters logo
BRIEF-Uniqure announces development and scale-up of manufacturing processes for Hemophilia B gene therapy program
July 21, 2017 / 11:27 AM / 5 months ago

BRIEF-Uniqure announces development and scale-up of manufacturing processes for Hemophilia B gene therapy program

July 21 (Reuters) - Uniqure NV

* Uniqure announces the successful development and scale-up of manufacturing processes for its Hemophilia B gene therapy program

* Uniqure NV - ‍manufacturing process to be leveraged in Huntington’s program, with production expected to begin before year end​

* Uniqure NV - ‍company expects to meet with U.S. Food and Drug Administration and European Medicines Agency in early fall​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below